Retinal Vein Occlusion (RVO) occurs when the vein draining blood from the retina is blocked, leading to complications such as macular edema and vision loss.

So a retinal vein occlusion is when there is an occlusion in the blood vessels of the retina that are particularly the veins, and it causes a lack of blood flow, or a lack of perfusion ...

Significant association between vitamin D deficiency and retinal vein occlusion No difference in vitamin D levels between central retinal vein occlusion and branch retinal vein occlusion subtypes ...

Roche, represented by Ali Abdulwahab Al Mutawa Commercial Company (AAW) in Kuwait, announced today that the European ...

Researchers have found that psoriasis significantly increases the risk of retinal vein occlusion (RVO) in patients with Type ...

Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American ...

Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...

NICE has recommended faricimab within its anticipated marketing authorisation, as an option for treating visual impairment caused by macular oedema after central or branch retinal vein occlusion in ...

OPUVIZ, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen's second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency IN ...

Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...